Mission Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $3.68M | Sell |
7,048
-1,122
| -14% | -$575K | 0.06% | 191 |
|
|
2026
Q2 | $4.06M | Buy |
8,170
+4,075
| +100% | +$1.81M | 0.05% | 202 |
|
|
2026
Q1 | $1.83M | Buy |
4,095
+39
| +1% | +$18.2K | 0.04% | 227 |
|
|
2025
Q4 | $1.84M | Buy |
4,056
+89
| +2% | +$38.4K | 0.04% | 224 |
|
|
2025
Q3 | $1.55M | Sell |
3,967
-1,742
| -31% | -$728K | 0.03% | 250 |
|
|
2025
Q2 | $2.54M | Sell |
5,709
-1,202
| -17% | -$554K | 0.05% | 185 |
|
|
2025
Q1 | $3.35M | Buy |
6,911
+859
| +14% | +$400K | 0.08% | 136 |
|
|
2024
Q4 | $2.44M | Sell |
6,052
-575
| -9% | -$267K | 0.06% | 163 |
|
|
2024
Q3 | $3.08M | Buy |
6,627
+815
| +14% | +$391K | 0.07% | 138 |
|
|
2024
Q2 | $2.72M | Sell |
5,812
-1,995
| -26% | -$866K | 0.07% | 144 |
|
|
2024
Q1 | $3.26M | Buy |
7,807
+2,914
| +60% | +$1.23M | 0.09% | 130 |
|
|
2023
Q4 | $1.99M | Buy |
4,893
+212
| +5% | +$78.3K | 0.06% | 148 |
|
|
2023
Q3 | $1.63M | Buy |
4,681
+70
| +2% | +$24.5K | 0.06% | 157 |
|
|
2023
Q2 | $1.62M | Buy |
4,611
+21
| +0.5% | +$7.08K | 0.06% | 154 |
|
|
2023
Q1 | $1.45M | Buy |
4,590
+64
| +1% | +$19.2K | 0.06% | 171 |
|
|
2022
Q4 | $1.31M | Buy |
4,526
+164
| +4% | +$50K | 0.06% | 167 |
|
|
2022
Q3 | $1.26M | Buy |
4,362
+96
| +2% | +$27.6K | 0.07% | 156 |
|
|
2022
Q2 | $1.2M | Buy |
4,266
+658
| +18% | +$176K | 0.06% | 168 |
|
|
2022
Q1 | $942K | Buy |
3,608
+492
| +16% | +$117K | 0.04% | 211 |
|
|
2021
Q4 | $684K | Sell |
3,116
-55
| -2% | -$10.7K | 0.03% | 250 |
|
|
2021
Q3 | $575K | Buy |
3,171
+57
| +2% | +$11.1K | 0.03% | 261 |
|
|
2021
Q2 | $628K | Buy |
3,114
+63
| +2% | +$13.2K | 0.03% | 250 |
|
|
2021
Q1 | $656K | Buy |
3,051
+490
| +19% | +$108K | 0.04% | 211 |
|
|
2020
Q4 | $605K | Buy |
2,561
+332
| +15% | +$76.2K | 0.04% | 196 |
|
|
2020
Q3 | $607K | Buy |
2,229
+44
| +2% | +$12.1K | 0.05% | 170 |
|
|
2020
Q2 | $634K | Buy |
2,185
+52
| +2% | +$14.1K | 0.05% | 159 |
|
|
2020
Q1 | $508K | Sell |
2,133
-7
| -0.3% | -$1.61K | 0.06% | 160 |
|
|
2019
Q4 | $469K | Buy |
2,140
+125
| +6% | +$25.3K | 0.05% | 189 |
|
|
2019
Q3 | $341K | Sell |
2,015
-459
| -19% | -$81.2K | 0.04% | 212 |
|
|
2019
Q2 | $454K | Sell |
2,474
-264
| -10% | -$46.2K | 0.05% | 181 |
|
|
2019
Q1 | $504K | Buy |
2,738
+231
| +9% | +$42.7K | 0.06% | 169 |
|
|
2018
Q4 | $415K | Buy |
2,507
+465
| +23% | +$80.6K | 0.05% | 170 |
|
|
2018
Q3 | $394K | Hold |
2,042
| – | – | 0.05% | 176 |
|
|
2018
Q2 | $347K | Buy |
+2,042
| New | +$317K | 0.05% | 177 |
|
Other funds holding VRTX
Mission Wealth Management's VRTX Position: Q3 2026 in Review
Mission Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q3 2026, selling an estimated $575K and leaving 7,048 shares worth $3.68M. The position accounts for 0.06% of the portfolio, ranked #191.
Mission Wealth Management first reported a position in VRTX in Q2 2018 and has held it in 34 quarters since. The position peaked at $4.06M in Q2 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Mission Wealth Management held 7,048 shares of Vertex Pharmaceuticals worth $3.68M as of Q3 2026.
- Mission Wealth Management sold 1,122 Vertex Pharmaceuticals shares in Q3 2026, an estimated $575K.
- Vertex Pharmaceuticals made up 0.06% of Mission Wealth Management's portfolio in Q3 2026, its #191 holding.
- Mission Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 34 quarters since.
- Mission Wealth Management's Vertex Pharmaceuticals position peaked at $4.06M in Q2 2026.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Mission Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.